Dade Behring cited in FDA warning letter for delays in correcting problems with IVD preservatives.
This article was originally published in The Gray Sheet
Executive SummaryDADE BEHRING DELAYS IN CORRECTING PROBLEMS WITH PRESERVATIVES is alleged by FDA in a Nov. 25 warning letter to the company. Following an Oct. 14-17 inspection of the firm's Cupertino and San Jose, California facilities, FDA found that problems identified as "critical, safety or regulatory in nature" did not receive quick corrective action.
You may also be interested in...
The North American trade organization’s new website offers consumers a gateway into the world of fragrance. Providing a “deep dive” into 50 fragrance ingredients, as well as overviews of perfumery, key regulations, and industry safety practices and sustainability efforts, the site extends FCA’s work to engage and inform consumers at a time of growing interest in manufactured scents.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.